Year-end report October – December 2023
Business Highlights during the fourth quarter 2023
- Encouraging preclinical data using uTREAT in non-small cell lung cancer
- Announcing the submission of the clinical trial application to the European Medicines Agency for the investigation of uTRACE in a phase 2 trial
- Advancing the theranostics by ongoing momentum in development pipeline with data and regulatory progress
Copenhagen, Denmark, 22 February 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the the Year-end report October – December 31, 2023. The Year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
“We had a busy quarter, announcing key data for uTREAT in non-small lung cancer as we continue to validate our theranostics approach for improved diagnosis and treatment of certain cancers.” Stated Curasight’s CEO Ulrich Krasilnikoff. “We also spent time during the quarter planning our updated strategy – which we announced following the end of the period - to accelerate our clinical development in parallel for uTREAT and uTRACE. We believe Curasight’s value in the future will be driven by this and our ability to build partnerships to support later stage clinical development and towards commercialization. To execute on our goals, we need to have a stable financial foundation and therefore we launched a rights issue at the start of the new year, providing an opportunity for shareholders to support the further development of the company by injecting more funding into the business.”
Q4 (2023-10-01 – 2023-12-31)
- Gross loss amounted to kDKK -5,493 (kDKK -3,792)
- Operating loss amounted to kDKK -7,907 (kDKK -7,066)
- Loss before tax amounted to kDKK -7,892 (kDKK -7,095)
- Loss for the period amounted to kDKK -6,413 (kDKK -6,810)
- Total assets amounted to kDKK 38,742 (kDKK 59,667)
- Equity ratio amounted to 81,0% (96,5%)
- Earnings per share amounted to DKK -0,32 (DKK -0,34)
Q1-Q4 (2023-01-01 – 2023-12-31)
- Gross loss amounted to kDKK -25,729 (kDKK -11,488)
- Operating loss amounted to kDKK -33,214 (kDKK -18,862)
- Loss before tax amounted to kDKK -33,220 (kDKK -19,488)
- Loss for the year amounted to kDKK -26,169 (kDKK -18,349)
- Total assets amounted to kDKK 38,742 (kDKK 59,667)
- Equity ratio amounted to 81,0% (96,5%)
- Earnings per share amounted to DKK -1,32 (DKK -0,92)
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.